Home > News > Latest > Provectus Algae Expands into New Large-Scale Microalgae Biomanufacturing Facility

Diagnostics

Provectus Algae Expands into New Large-Scale Microalgae Biomanufacturing Facility

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility.

“Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into this next phase of the company's growth”

Located in Noosaville, Australia, the new site is expected to be operational by the end of 2021 and will complement the company’s existing facility to deliver new algae-made products to the market. The new facility will support the production of a high-performance food colouring which is currently in late stage of development. Once completed, the facility will have a 200,000 litre production capacity and expanded R&D operations to support early-stage product development and partnerships for the Food & Beverage sector. Provectus’s inaugural pilot facility will subsequently be converted to support the commercial production of a separate high-value product that is currently undergoing product testing. The company expects further expansion in the near term with plans for a supplementary 1 million litre facility already underway to support the commercialisation of multiple products already in the company development pipeline.

Provectus has engaged global food & beverage companies to craft a tailored development pipeline of products most relevant to the strengths of the company’s biomanufacturing platform. The flexibility of the company’s unique platform approach is evidenced by the speed at which lead products have moved through the development pipeline to commercial readiness.

“This is just the tip of the iceberg for Provectus Algae. The stage of development we are now at with our production platform gives us a clear line of sight to deliver some really exciting products to the food and beverage marketplace,” said Nusqe Spanton, Founder and CEO of Provectus Algae. “What we are able to achieve for our commercial partners is simply not comparable to any other offering in the marketplace. Thanks to algae, we are able to benefit from a 3.5-billion-year head start in producing some of the world’s most coveted ingredients.”

The Provectus platform addresses supply chain challenges by providing end-to-end services from product development to large-scale biomanufacturing. Importantly, the manufacturing platform is able to go from bench to industrial-scale seamlessly with a continuity of their novel production technology.

“Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into this next phase of the company's growth,” Spanton added.

ABOUT PROVECTUS ALGAE
Provectus Algae is an Australian biotech company that programs algae to produce the world's most valuable specialty ingredients. By accelerating nature, their team is able to optimise unique microalgae to produce a whole new range of natural products, in a process described as “precision photosynthesis”. Using next-generation techniques the company has also developed a synthetic biology stack that complements and competes with existing production platforms to deliver high-performance and sustainable products.

Spotlight

Other News

Medical

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis, Inc. | February 05, 2024

Personalis, Inc. a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform. “We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.” Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research. This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry. Together, we can accelerate the development of personalized therapies and make a real difference in the lives of patients.” ClearNote Health’s Epigenomics Platform represents a groundbreaking advance in cancer detection, offering real-time insights into disease-specific pathways. By tracking changes in 5hmC levels coupled with artificial intelligence-based analytical methods, the platform can detect cancer earlier, monitor disease progression, understand mechanisms of resistance, and identify promising drug targets and biomarkers. These insights are invaluable for optimizing drug development programs and delivering more effective treatments to patients. The Epigenomics Platform identifies changes in gene activation and gene regulation by labeling specific changes in the 5hmC landscape from plasma-derived cell-free DNA. This rich biological information, as part of clinical trials, enables the monitoring of cancer therapies in real time and contributes to an understanding of drug resistance mechanisms. The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry. About ClearNote Heath, Inc. ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health’s first commercially available test is the Avantect™ Pancreatic Cancer Test, which detects the presence of pancreatic cancer signals in patients at high risk of the disease, including those recently diagnosed with Type 2 diabetes. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.